Reliable, high-throughput KV7 assays paired with expert interpretation enable faster progression of pain and epilepsy drug discovery programmes.
Highly-validated screening assays developed by Metrion are capable of confidently identifying modulators of the lysosomal TRPML1 channel. The TRPML1 variant that lacks the endo-lysosomal retention sequences (TRPML1-4A) is used, enabling the channel to express at the plasma membrane. As such, channel behaviour can be successfully characterised by:
Read our case study: Development of TRPML1-4A assays across manual, automated patch-clamp, and fluorescence-based platforms
Contact Metrion to advance your preclinical drug discovery project
Reliable, high-throughput KV7 assays paired with expert interpretation enable faster progression of pain and epilepsy drug discovery programmes.
By accurately defining the drug exposure levels that affect QRS duration, researchers can establish safety margins, prioritise lower-risk compounds, and reduce the chance of late-stage failures due to cardiac toxicity